Brokerages Set STAAR Surgical (NASDAQ:STAA) Target Price at $101.67

Shares of STAAR Surgical (NASDAQ:STAA – Get Rating) have earned a consensus recommendation of “Buy” from the nine analysts that are presently covering the firm, MarketBeat.com reports. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $95.14.

STAA has been the topic of several research analyst reports. Benchmark raised shares of STAAR Surgical from a “hold” rating to a “buy” rating and set a $97.00 price objective on the stock in a research report on Monday, March 28th. Zacks Investment Research raised shares of STAAR Surgical from a “hold” rating to a “buy” rating and set a $56.00 price objective on the stock in a research report on Friday. Canaccord Genuity Group raised their price target on shares of STAAR Surgical from $81.00 to $89.00 and gave the stock a “buy” rating in a research report on Tuesday, April 26th. StockNews.com started coverage on shares of STAAR Surgical in a research report on Thursday, March 31st. They set a “hold” rating on the stock. Finally, BTIG Research reaffirmed a “buy” rating and set a $98.00 price target on shares of STAAR Surgical in a research report on Saturday, April 23rd.

In other STAAR Surgical news, VP James E. Francese sold 922 shares of the stock in a transaction dated Monday, March 21st. The shares were sold at an average price of $74.62, for a total transaction of $68,799.64. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 3.60% of the company’s stock.

A number of institutional investors have recently made changes to their positions in the business. Allegheny Financial Group LTD acquired a new stake in shares of STAAR Surgical in the 4th quarter valued at approximately $25,000. Rise Advisors LLC acquired a new stake in shares of STAAR Surgical in the 4th quarter valued at approximately $25,000. Covestor Ltd acquired a new stake in shares of STAAR Surgical in the 4th quarter valued at approximately $39,000. Lazard Asset Management LLC boosted its stake in shares of STAAR Surgical by 131.1% in the 1st quarter. Lazard Asset Management LLC now owns 684 shares of the medical instruments supplier’s stock valued at $54,000 after purchasing an additional 388 shares in the last quarter. Finally, Lindbrook Capital LLC acquired a new stake in shares of STAAR Surgical in the 4th quarter valued at approximately $59,000. Hedge funds and other institutional investors own 89.93% of the company’s stock.

STAA stock traded up $3.99 during trading hours on Friday, reaching $58.18. The stock had a trading volume of 601,021 shares, compared to its average volume of 645,256. The stock has a market capitalization of $2.78 billion, a PE ratio of 100.31 and a beta of 1.18. The stock has a 50-day simple moving average of $66.72 and a 200 day simple moving average of $81.05. STAAR Surgical has a fifty-two week low of $49.03 and a fifty-two week high of $163.08.

STAAR Surgical (NASDAQ:STAA – Get Rating) last announced its quarterly earnings results on Wednesday, May 4th. The medical instruments supplier reported $0.21 EPS for the quarter, beating analysts’ consensus estimates of $0.10 by $0.11. The firm had revenue of $63.20 million during the quarter, compared to analysts’ expectations of $60.53 million. STAAR Surgical had a net margin of 11.98% and a return on equity of 12.78%. The company’s revenue for the quarter was up 24.5% compared to the same quarter last year. During the same quarter last year, the company posted $0.13 earnings per share. As a group, sell-side analysts predict that STAAR Surgical will post 0.61 earnings per share for the current fiscal year.

About STAAR Surgical (Get Rating)

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness.

Further Reading